AQST Latest Headlines

Reaffirming Buy on Anaphylm: Navigable FDA CRL, Limited Incremental Costs, and Intact 2027 Approval Timeline

at www.tipranks.com (Tue, 3-Feb 6:26 AM)

AQST’s FDA Roadblock Is Packaging, Not Product—Anaphylm’s Path Forward Looks Manageable

Market Chameleon (Mon, 2-Feb 10:29 AM)

FDA Raises Packaging Concerns for Aquestive’s Anaphylm, but Company Eyes Rapid Resolution and Global Expansion

Market Chameleon (Mon, 2-Feb 8:39 AM)

Buy Rating Reaffirmed on Aquestive Therapeutics as Operational FDA Setbacks De-Risk Anaphylm’s Path to Approval

at www.tipranks.com (Mon, 2-Feb 2:25 PM)

Analysts’ Top Healthcare Picks: Aquestive Therapeutics (AQST), Skye Bioscience (SKYE)

at www.tipranks.com (Mon, 2-Feb 2:10 PM)

Buy Rating Maintained on Aquestive Therapeutics as FDA CRL Seen as Operational Setback with Manageable Risk and Attractive Long-Term Risk-Reward

at www.tipranks.com (Mon, 2-Feb 11:16 AM)

Peakstone Realty Trust, Aquestive Therapeutics, Opera And Other Big Stocks Moving Higher On Monday

at www.benzinga.com (Mon, 2-Feb 10:44 AM)

Analysts Offer Insights on Healthcare Companies: Roche Holding AG (OtherRHHVF), Aquestive Therapeutics (AQST) and 60 Degrees Pharmaceuticals, Inc. (SXTP)

at www.tipranks.com (Mon, 2-Feb 10:10 AM)

Analysts Offer Insights on Healthcare Companies: Aquestive Therapeutics (AQST) and Artivion (AORT)

at www.tipranks.com (Mon, 2-Feb 10:00 AM)

FDA Issues Complete Response Letter on Anaphylm Application

at www.tipranks.com (Mon, 2-Feb 7:35 AM)

FDA Review for Anaphylm Remains Ongoing: Aquestive Pursues Global Regulatory Approvals Amid Unresolved Application Issues

Market Chameleon (Fri, 9-Jan 7:51 AM)